New data reveals potential 1st therapy for post-GLP weight loss

Shares of Fractyl Health (Nasdaq: GUTS) were up nearly 25% at $1.26 in pre-market activity, after it announced what it called “ground-breaking” results from the REMAIN-1 Midpoint Cohort, supporting the potential for Revita to be the first therapy to preserve weight loss after GLP-1 drug discontinuation.

Revita DMR System, is an outpatient procedural therapy designed to modify duodenal dysfunction.

At three months, Revita-treated patients lost an additional 2.5% total body weight after stopping tirzepatide, Eli Lilly’s (NYSE: LLY) blockbuster diabetes and obesity drug, while sham patients regained 10% (p=0.014). These results are clinically and statistically significant and provide randomized, blinded evidence that drug-free, durable weight maintenance is possible. They further support Revita as a potential first-in class treatment in a new therapeutic category in obesity care: post-GLP-1 weight maintenance.